496 hasil
Menampilkan 1–20 · 0,26 detik · RSS
Bladder Cancer
Scopus
ISSN 2352-3735 · SAGE Publishing · 496 artikel di indeks
-
Artikel Jurnal
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients
Background Neoadjuvant chemotherapy followed by radical cystectomy (NACT-RC) is the prevailing standard of care for muscle-invasive bladder cancer (MIBC), but trimodality treatment (TMT) using chemoradiation after transurethral resection of bladder tumor (TURBT) is an effective alternative in…
-
Artikel Jurnal
Radiogenomic analysis of muscle-invasive bladder cancer using CT-based texture analysis
Background Urothelial bladder cancer exhibits marked molecular and clinical heterogeneity. While genomic and transcriptomic profiling of muscle-invasive bladder cancer (MIBC) has revealed recurrent alterations with therapeutic and prognostic relevance, limited access to molecular testing constrains…
-
Artikel Jurnal
Guideline-recommended post-operative intravesical chemotherapy and cystoscopic surveillance among patients with low- and intermediate-risk non-muscle invasive bladder cancer
Introduction We sought to characterize concordance of surveillance and treatment patterns in a large community-based healthcare system with the American Urologic Association/Society of Urologic Oncology (AUA/SUO) guideline for low- and intermediate-risk non-muscle invasive bladder cancer (NMIBC)…
-
Artikel Jurnal
Intra- and extravesical recurrence after epirubicin-based hyperthermic intravesical chemotherapy (HIVEC) in patients with NMIBC and BCG failure: A multicenter retrospective Observational Study
Background Guidelines recommend intravesical Bacillus Calmette-Guérin (BCG) as adjuvant therapy for intermediate- and high-risk non-muscle-invasive bladder cancer after transurethral resection. In the event of BCG failure, hyperthermic intravesical chemotherapy (HIVEC) represents a treatment…
-
Artikel Jurnal
Difficult conversations in bladder cancer survivorship: Integrating mental health and intimacy into routine urologic care
Introduction Bladder cancer survivorship extends beyond oncologic control and includes significant psychological distress, demoralization, sexual dysfunction, and identity disruption. Despite their clinical relevance, structured approaches to difficult conversations in bladder cancer care remain…
-
Artikel Jurnal
Induction and characterization of neoplastic bladder tumors in a transgenic porcine model
Background Large animal models of bladder cancer are lacking. Objective This study aimed to develop and characterize a transgenic porcine model of bladder cancer (BC) using Oncopigs expressing Cre-inducible KRAS G12D and TP53 R167H mutations. Methods Eleven female Oncopigs underwent tumor induction…
-
Artikel Jurnal
Proceedings of the first international NMIBC consensus classification meeting
Non–muscle invasive bladder cancer (NMIBC) is a biologically and clinically heterogeneous disease, accounting for approximately 75% of bladder cancer cases. Over the past decade, multiple RNA-based molecular classification systems for NMIBC have been proposed, demonstrating associations with tumor…
-
Artikel Jurnal
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression
Background The latest bladder cancer (BC) urine tests based on multiple genomic and/or epigenomic markers detect BC with high sensitivity and specificity. The GALEAS Bladder (GB) gene panel covers several actionable mutations, including in FGFR3. Objective To modify GB to detect FGFR3 fusions as…
-
Artikel Jurnal
Under-reporting of carcinoma in situ in patients with high-grade papillary non–muscle-invasive bladder cancer
Background Concomitant carcinoma in situ (CIS) with high-grade papillary urothelial carcinoma impacts patient risk stratification and treatment. However, on identification of a high-grade papillary lesion, pathologists may be disinclined to search for possible CIS. Several newer agents for bacillus…
-
Artikel Jurnal
Computational pathology in bladder cancer: A scoping review
Background Histologic assessment of tumor tissue is fundamental to the diagnosis and management of bladder cancer. As digital pathology becomes more widely adopted and artificial intelligence (AI) tools rapidly advance, computational pathology has emerged as a promising avenue for extracting…
-
Artikel Jurnal
Adjuvant immunotherapy for muscle-invasive urothelial carcinoma: Considerations for targeting patients
While neoadjuvant chemotherapy and radical surgery represent mainstay treatments for muscle-invasive urothelial carcinoma (MIUC), recurrence with lethal metastasis remains high and highlights the need for adjuvant therapies in MIUC, like immunotherapy, already in use for metastatic UC with…
-
Artikel Jurnal
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer
Introduction Radical cystectomy or trimodal therapy are treatment options for non-metastatic bladder cancer. However, there is limited evidence guiding post-treatment follow-up regimens, resulting in variations in care. Objective A Swiss consensus meeting aimed to identify gaps in follow-up…
-
Artikel Jurnal
Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract
Background Metastasis-directed therapy (MDT) for oligometastatic cancer is utilized for genitourinary malignancies including prostate and kidney cancers. Clinical research on MDT for urothelial carcinoma (UC) remains sparse, especially as systemic therapy advances have improved outcomes. Objective…
-
Artikel Jurnal
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab
Enfortumab vedotin with pembrolizumab (EV + pembro) has transformed first-line treatment of advanced urothelial carcinoma (aUC). No prospective data are available evaluating outcomes of different therapies following progression on EV + pembro. Patients who received first-line EV + pembro and had…
-
Artikel Jurnal
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population
Background Gene polymorphisms can lead to differential production of inflammatory proteins associated with cancer development. Prior explorations of the association of single nucleotide polymorphisms (SNPs) of monocyte chemoattractant protein (MCP-1/CCL2) and its receptor, CCR2, to bladder cancer…